<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32651875</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2240-2993</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neurologica Belgica</Title><ISOAbbreviation>Acta Neurol Belg</ISOAbbreviation></Journal><ArticleTitle>Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.</ArticleTitle><Pagination><StartPage>1591</StartPage><EndPage>1597</EndPage><MedlinePgn>1591-1597</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13760-020-01430-2</ELocationID><Abstract><AbstractText>Edaravone is a free radical scavenger that has been recently approved for treatment of Amyotrophic lateral sclerosis (ALS) to delay&#xa0;functional decline. We aim to evaluate edaravone efficacy and safety in ALS patients in the main neurology tertiary center in Kuwait over 72-week period. We conducted a prospective observational cohort study in the main tertiary hospital over 72-week period from July 2018 until January 2020. Patients were assessed at baseline, 24, 48 and 72&#xa0;weeks of therapy using ALSFRS-R score, MRC sum score, FVC value, among other parameters. Seventeen consecutive patients were evaluated. All patients were assessed at baseline, 24 and 48&#xa0;weeks, while 9 patients (52.9%) were further assessed at 72&#xa0;weeks. There was a statistically significant decline of ALSFRS-R at 72&#xa0;weeks, MRC sum score at 48 and 72&#xa0;weeks, while the decline in FVC was not statistically significant. Glycosuria was found in only one patient. Our study showed significant functional decline after 1&#xa0;year of edaravone therapy with preserved respiratory function. The drug had a high level of dissatisfaction among our cohort despite having a high safety profile.</AbstractText><CopyrightInformation>&#xa9; 2020. Belgian Neurological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Ismail Ibrahim</ForeName><Initials>II</Initials><Identifier Source="ORCID">0000-0002-9788-7044</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ibn Sina Hospital, Gamal Abdel Nasser Street, Sabah Medical Area, Box 25427, 13115, Kuwait City, Kuwait. dr.ismail.ibrahim2012@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massoud</LastName><ForeName>Fathi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ibn Sina Hospital, Gamal Abdel Nasser Street, Sabah Medical Area, Box 25427, 13115, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamel</LastName><ForeName>Walaa Ahmed</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ibn Sina Hospital, Gamal Abdel Nasser Street, Sabah Medical Area, Box 25427, 13115, Kuwait City, Kuwait.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Beni-Suef University, Bani Sweif, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Hashel</LastName><ForeName>Jasem Youssef</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ibn Sina Hospital, Gamal Abdel Nasser Street, Sabah Medical Area, Box 25427, 13115, Kuwait City, Kuwait.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Health Sciences Centre, Kuwait University, Safat, Kuwait.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Acta Neurol Belg</MedlineTA><NlmUniqueID>0247035</NlmUniqueID><ISSNLinking>0300-9009</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007730" MajorTopicYN="N" Type="Geographic">Kuwait</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Kuwait</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32651875</ArticleId><ArticleId IdType="doi">10.1007/s13760-020-01430-2</ArticleId><ArticleId IdType="pii">10.1007/s13760-020-01430-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942&#x2013;955</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K (2009) Motor neuron disease: the bare essentials. Pract Neurol 9(5):303&#x2013;309</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.188151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, Menzies FM, Manning P et al (2002) Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler Other Motor Neuron Disord 3:75&#x2013;85</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202760196048</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cutsem P, Dewil M, Robberecht W, Van Den Bosch L (2005) Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2(3&#x2013;4):147&#x2013;159</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39(2):733&#x2013;748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 7:241&#x2013;245</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G et al (2014) Confirmatory double-blind, parallel-group, placebocontrolled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15:610&#x2013;617</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Sakata T, Palumbo J, Akimoto M (2015) A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS). Neurology 86:3&#x2013;189</Citation></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, Wiedau-Pazos M, Liu S, Zhang J et al (2020) Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve 61(2):218&#x2013;221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169(1&#x2013;2):13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505&#x2013;512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, Martinelli I, Bertolin C, Pegoraro E, Edaravone Study Group et al (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci 404:47&#x2013;51</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M et al (2019) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 11:1&#x2013;10</Citation></Reference><Reference><Citation>Palumbo JM, Hubble J, Apple S, Takei K, Tsuda K, Liu S et al (2019) Post-hoc analyses of the edaravone clinical trials study 16 and study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. https://doi.org/10.1080/21678421.2019.1599955</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1599955</ArticleId><ArticleId IdType="pubmed">30982356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2014) Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegen Dis Manag 4:83&#x2013;102. https://doi.org/10.2217/nmt.13.74</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.13.74</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH (2006) Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 77:390&#x2013;392</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2019) SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol 10:109. https://doi.org/10.3389/fneur.2019.00109</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00109</ArticleId><ArticleId IdType="pubmed">30873101</ArticleId><ArticleId IdType="pmc">6403463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G et al (2014) Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 71(9):1134&#x2013;1142. https://doi.org/10.1001/jamaneurol.2014.1129</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JM, Kim SY, Park D, Park JS (2020) Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci 41(1):119&#x2013;123</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>